Speaking of Rituxan monitoring, we had a Dr. last week that ordered a CD20 for Rituxan therapy monitoring and he wanted to know how many B cells were present. Looking at the total lymph gate, there were about 70% T cells (CD3+), about 8% NK cells (CD56+16+/CD3-) which would leave about 22% that should have been B cells. I could not get those B cells to stain with CD19, CD20, or CD22. There was always a population totally negative (0% for all 3 B markers) which amounted to about 20%. I thought the Rituxan was only supposed to block CD20. Could someone shed some light on this problem for me. Avis Peters United Hospital Flow Cytometry Lab St. Paul, MN "Timothy Singleton, M.D." <tsingleton@smtpgw.beaumont.edu> wrote: > >Cytoplasmic CD79a. > >Tim Singleton, MD >Flow Cytometry >Beaumont Hospital >Royal Oak, MI > >>>> Paula Fukushima <pif@mail.nih.gov> 05/24/02 09:40AM >>> > >Hi List, > Does anyone have an idea of B cell antibodies to use to follow >disease >in B cell lymphomas >with patients now being given anti-CD22(Epratuzumab) and >anti-CD20(Rituxamab) besides CD19? > > Thanks, Paula > > >Paula Imus >Flow Cytometry >LP, NCI, NIH >10 Center Drive MSC-1500 >Bethesda, Md. 20892-1500 > > > > __________________________________________________________________ Your favorite stores, helpful shopping tools and great gift ideas. Experience the convenience of buying online with Shop@Netscape! http://shopnow.netscape.com/ Get your own FREE, personal Netscape Mail account today at http://webmail.netscape.com/
This archive was generated by hypermail 2b29 : Sun Jan 05 2003 - 19:26:11 EST